Back to Journals » Drug Design, Development and Therapy » Volume 9

Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin

Authors Wang H, Liu J, Zhao H

Received 16 May 2014

Accepted for publication 22 July 2014

Published 30 January 2015 Volume 2015:9 Pages 683—686


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Hongyu Wang, Jinbo Liu, Hongwei Zhao

Department of Vascular Medicine, Peking University Shougang Hospital, Beijing, People's Republic of China

Abstract: Type 2 diabetes mellitus (T2DM) has become a worldwide health problem, and the rate of it is growing greatly in the People's Republic of China every year. T2DM could cause macrovascular and microvascular complications that lead to an increase in arterial wall thickness, endothelial dysfunction, calcification, and – finally – to an increase in arterial stiffness and arterial dysfunction. Alogliptin, a new selective inhibitor of dipeptidyl peptidase 4, has shown its great antihyperglycemia effect in T2DM patients. The clinical trial data from the People's Republic of China was similar to other global and Asian trials. This could provide some choice for clinical physicians to the treatment of T2DM.

Keywords: type 2 diabetes mellitus, People's Republic of China, alogliptin, arterial function

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]